Missouri tracks PSE sales
This article was originally published in The Tan Sheet
Missouri becomes the fourth state to track sales of OTC pseudoephedrine-containing medicines with the National Precursor Log Exchange, the Consumer Healthcare Products Association announces March 8. NPLEx is a real-time, statewide electronic log that helps block illegal sales of PSE, a precursor used to create methamphetamine. CHPA offers the system to states for free as an alternative to moving PSE products to Rx only. So far only Colorado and Mississippi switched OTC PSE drugs to Rx to curb illegal sales and meth production (1"The Tan Sheet" Feb. 8, 2010).... Washington Senate votes to track PSE sales: The Washington state Senate passes a bill March 12 directing the state Board of Pharmacy to establish an electronic tracking system for PSE, ephedrine and phenylpropanolamine products by next July. The bill also raises the daily sales limit for drugs containing meth precursors to 3.6 grams to match the federal limit. Previously, the bill capped the daily total at 3 grams or a single package of any product with the ingredients. A similar bill passed the state house previously
You may also be interested in...
The Alabama state Senate March 9 passed a bill creating an electronic tracking system for sales of products with pseudoephedrine and ephedrine, precursors for methamphetamine. The bill, which awaits the governor's signature, modernizes paper logs that require retailers to record consumers' identifying information and purchases of PSE and ephedrine. The new system will notify retailers if a customer exceeds the sales limit for the drugs. Alabama is one of several states to require electronic tracking of PSE (1"The Tan Sheet" March 15, 2010, In Brief)
Mississippi lawmakers' decision to make all pseudoephedrine-containing drugs prescription-only will not prompt other states combating methamphetamine to do the same, the Consumer Healthcare Products Association predicts
The pharmaceutical industry and the UK government are beginning a series of round table discussions on the shape of the future voluntary drug pricing and access scheme (VPAS), ahead of the formal negotiations that are scheduled to start in April.